Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ] - Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009
Wed, January 28, 2009
Tue, January 27, 2009

Depomed to Present at Upcoming Conferences


//health-fitness.news-articles.net/content/2009/ .. /depomed-to-present-at-upcoming-conferences.html
Published in Health and Fitness on Tuesday, February 3rd 2009 at 7:26 GMT, Last Modified on 2009-02-03 07:27:03 by Market Wire   Print publication without navigation


MENLO PARK, Calif.--([ BUSINESS WIRE ])--Depomed, Inc. (NASDAQ:DEPO) announced today that president and chief executive officer, Carl A. Pelzel will provide corporate presentations at the following upcoming conferences:

  • BIO CEO and Investor Conference, February 10, 2009 at 11:15 a.m. PT
  • Roth OC Growth Conference, February 17, 2009 at 12:00 p.m. PT

The company will be webcasting its presentations and interested parties can access the live or archived presentations for up to 90 days on the company's website at [ www.depomed.com ].

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, [ www.depomedinc.com ].


Publication Contributing Sources